Related Experiment Video
Updated: Feb 6, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
The germline genetic component of drug sensitivity in cancer cell lines
Michael P Menden1,2, Francesco Paolo Casale2,3, Johannes Stephan2
1Oncology Innovative Medicines & Early Drug Development, AstraZeneca, Milton Science Park, Cambridge, CB4 0FZ, UK.
Abstract:
Patients with seemingly the same tumour can respond very differently to treatment. There are strong, well-established effects of somatic mutations on drug efficacy, but there is at-most anecdotal evidence of a germline component to drug response. Here, we report a systematic survey of how inherited germline variants affect drug susceptibility in cancer cell lines. We develop a joint analysis approach that leverages both germline and somatic variants, before applying it to screening data from 993 cell lines and 265 drugs. Surprisingly, we find that the germline contribution to variation in drug susceptibility can be as large or larger than effects due to somatic mutations. Several of the associations identified have a direct relationship to the drug target. Finally, using 17-AAG response as an example, we show how germline effects in combination with transcriptomic data can be leveraged for improved patient stratification and to identify new markers for drug sensitivity.
Insights
Inherited genetic variants (germline variants) significantly impact cancer drug response, sometimes more than tumor mutations. This finding aids in predicting treatment success and identifying new drug sensitivity markers.
Area of Science:
- Genomics
- Pharmacogenomics
- Cancer Biology
Background:
- Individual cancer patients exhibit varied responses to the same treatments.
- Somatic mutations are known to influence drug efficacy, but the role of germline variants is less understood.
Purpose of the Study:
- To systematically investigate the impact of inherited germline variants on cancer drug susceptibility.
- To develop and apply a joint analysis method integrating germline and somatic genetic data for drug response studies.
Main Methods:
- A systematic survey of germline variants' effect on drug susceptibility was conducted.
- A novel joint analysis approach combining germline and somatic variants was developed.
- The approach was applied to screening data from 993 cancer cell lines across 265 drugs.
Main Results:
- Germline variants were found to contribute significantly, often as much or more than somatic mutations, to variations in drug susceptibility.
- Several identified germline variant associations showed a direct relationship with drug targets.
- The study demonstrated how germline effects, combined with transcriptomic data, can improve patient stratification for drugs like 17-AAG.
Conclusions:
- Inherited germline variants play a substantial, often underestimated, role in cancer drug response.
- Integrating germline genetics into cancer drug response analysis offers new avenues for personalized medicine and biomarker discovery.
Related Concept Videos
01:30Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
01:16Cell Lines
01:23Components of Stress
Interestingly, the hidden cube faces also experience these stresses, equal and...
01:24Components of Language
02:16Genetics of Speciation
01:25What is Population Genetics?